One Health drivers of antibacterial resistance: Quantifying the relative impacts of human, animal and environmental use and transmission.
Antibacterial resistance
Antibacterial usage
Mathematical model
One health
Thailand
Transmission
Journal
One health (Amsterdam, Netherlands)
ISSN: 2352-7714
Titre abrégé: One Health
Pays: Netherlands
ID NLM: 101660501
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
09
11
2020
revised:
20
01
2021
accepted:
21
01
2021
entrez:
1
3
2021
pubmed:
2
3
2021
medline:
2
3
2021
Statut:
epublish
Résumé
Antibacterial resistance (ABR) is a major global health security threat, with a disproportionate burden on lower-and middle-income countries (LMICs). It is not understood how 'One Health', where human health is co-dependent on animal health and the environment, might impact the burden of ABR in LMICs. Thailand's 2017 "National Strategic Plan on Antimicrobial Resistance" (NSP-AMR) aims to reduce AMR morbidity by 50% through 20% reductions in human and 30% in animal antibacterial use (ABU). There is a need to understand the implications of such a plan within a One Health perspective. A model of ABU, gut colonisation with extended-spectrum beta-lactamase (ESBL)-producing bacteria and transmission was calibrated using estimates of the prevalence of ESBL-producing bacteria in Thailand. This model was used to project the reduction in human ABR over 20 years (2020-2040) for each One Health driver, including individual transmission rates between humans, animals and the environment, and to estimate the long-term impact of the NSP-AMR intervention. The model predicts that human ABU was the most important factor in reducing the colonisation of humans with resistant bacteria (maximum 65.7-99.7% reduction). The NSP-AMR is projected to reduce human colonisation by 6.0-18.8%, with more ambitious targets (30% reductions in human ABU) increasing this to 8.5-24.9%. Our model provides a simple framework to explain the mechanisms underpinning ABR, suggesting that future interventions targeting the simultaneous reduction of transmission and ABU would help to control ABR more effectively in Thailand.
Identifiants
pubmed: 33644290
doi: 10.1016/j.onehlt.2021.100220
pii: S2352-7714(21)00010-0
pmc: PMC7892992
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100220Subventions
Organisme : Medical Research Council
ID : MR/R00241X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R014922/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S004769/1
Pays : United Kingdom
Investigateurs
Matthew B Avison
(MB)
Nour Alhusein
(N)
Ross D Booton
(RD)
Henry Buller
(H)
Boonrat Chantong
(B)
Nisanart Charoenlap
(N)
Natacha Couto
(N)
Punyawee Dulyayangkul
(P)
Edward Feil
(E)
Marjorie J Gibbon
(MJ)
Virginia C Gould
(VC)
Helen Lambert
(H)
Aronrag Meeyai
(A)
Skorn Mongkolsuk
(S)
Varapon Montrivade
(V)
Emma Pitchforth
(E)
Kornrawan Phoonsawad
(K)
Nuchanart Rangkadilok
(N)
Parntep Ratanakorn
(P)
Kristen K Reyher
(KK)
Walasinee Sakcamduang
(W)
Jutamaad Satayavivad
(J)
Andrew C Singer
(AC)
Kwanrawee Sirikanchana
(K)
Luechai Sringernyuang
(L)
Tawit Suriyo
(T)
Sarin Suwanpakdee
(S)
Visanu Thamlikitkul
(V)
Katherine Me Turner
(KM)
Lucy Vass
(L)
Kantima Wichuwaranan
(K)
Anuwat Wiratsudakul
(A)
Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
Declarations of interest: none
Références
Antibiotics (Basel). 2019 Mar 25;8(1):
pubmed: 30934638
J Med Assoc Thai. 2016 Mar;99(3):270-5
pubmed: 27276737
R Soc Open Sci. 2017 Apr 5;4(4):161067
pubmed: 28484624
Clin Infect Dis. 2016 Aug 1;63(3):310-8
pubmed: 27143671
Nat Microbiol. 2019 Sep;4(9):1432-1442
pubmed: 31439928
Pathog Glob Health. 2014 Jul;108(5):235-45
pubmed: 25146935
J Antimicrob Chemother. 2019 Mar 1;74(3):541-546
pubmed: 30544186
PLoS One. 2011 Feb 16;6(2):e17038
pubmed: 21359229
Lancet. 2016 Jan 9;387(10014):176-87
pubmed: 26603922
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Southeast Asian J Trop Med Public Health. 2008 May;39(3):425-33
pubmed: 18564681
BMJ. 2017 Sep 5;358:j3415
pubmed: 28874352
Ecohealth. 2019 Sep;16(3):404-409
pubmed: 31250160
BMC Med. 2019 Apr 24;17(1):81
pubmed: 31014341
Microbiome. 2016 Oct 7;4(1):54
pubmed: 27717408
Emerg Infect Dis. 2002 Apr;8(4):347-54
pubmed: 11971765
Antimicrob Resist Infect Control. 2013 Nov 18;2:31
pubmed: 24237856
Science. 2017 Sep 29;357(6358):1350-1352
pubmed: 28963240
Philos Trans R Soc Lond B Biol Sci. 2015 Jun 5;370(1670):20140083
pubmed: 25918441
Lancet. 2012 Dec 15;380(9859):2197-223
pubmed: 23245608
Int J Environ Res Public Health. 2019 Oct 05;16(19):
pubmed: 31590350
Lancet. 2011 Jan 15;377(9761):228-41
pubmed: 21146207
Lancet. 2016 Jan 9;387(10014):168-75
pubmed: 26603918
BMC Med. 2018 Aug 23;16(1):137
pubmed: 30134939
Science. 2019 Sep 20;365(6459):
pubmed: 31604207
J Antimicrob Chemother. 2012 Jul;67(7):1769-74
pubmed: 22514260
BMJ Glob Health. 2017 Jul 13;2(2):e000378
pubmed: 29225939
J Antimicrob Chemother. 2010 Apr;65(4):666-8
pubmed: 20106863
J Med Microbiol. 2011 May;60(Pt 5):619-624
pubmed: 21292857